Company ProfilePremium

ImpediMed Limited

Company Profile Analysis

Ticker: IPD.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
ImpediMed Limited - Company showcase

Year Founded & Workforce

1999

76 Employees

ImpediMed Limited logo

ImpediMed Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ImpediMed Limited Overview

ImpediMed is a small-cap Australian medical-technology company that commercialises bioimpedance spectroscopy (BIS) through its SOZO® Digital Health Platform — a hand-and-foot-plate measurement device paired with cloud software (MySOZO) that delivers non-invasive fluid and tissue-composition metrics in roughly 30 seconds. Its anchor indication is the early detection of breast-cancer-related lymphoedema (BCRL) via the proprietary L-Dex® score, for which ImpediMed describes itself as the only company offering FDA-cleared BIS technology. Commercial traction rests on three pillars built over 2023–2026: inclusion of BIS in NCCN Survivorship Guidelines and NAPBC breast-centre standards, a dedicated CPT code (93702), and US payer coverage that reached 95.0% of covered lives (331M) by June 2026. Around 90% of revenue is US-derived. The company is now extending SOZO into heart failure (HF-Dex) and GLP-1-era body composition, but remains loss-making (FY2026 net loss A$24.9M on A$14.6M revenue), heavily diluted, and dependent on further capital.


What the company does

ImpediMed designs, manufactures (via outsourced/contract arrangements; manufacturer of record on FDA filings is ImpediMed Limited, Australia) and sells medical devices that apply bioimpedance spectroscopy — passing a low-level electrical current through the body across a spectrum of frequencies — to estimate extracellular fluid, intracellular fluid, total body water, and body-composition parameters (fat mass, fat-free mass, skeletal muscle mass). The flagship SOZO system (and successor SOZO Pro) is used under physician direction for:

Lymphoedema assessment: (L-Dex®), primarily in breast-cancer survivorship programmes — the "SOZO Core Business";

Heart failure fluid monitoring: (HF-Dex), including patients with cardiac implantable devices (SOZO Pro clearance, Oct 2023);

  • Protein-calorie malnutrition / body composition, including the newly targeted GLP-1 weight-management and sarcopenia use-cases.

Company's own description (paraphrased from FY2026 H1 and FY2026 Q4 releases)

ImpediMed describes itself as a medical technology company using BIS to generate data that maximise patient health, producing the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked and ARTG-listed for multiple indications (lymphoedema, heart failure, protein-calorie malnutrition), and sold in select markets globally. It positions SOZO as part of the patient journey from active cancer treatment through long-term survivorship monitoring, and frames the large cancer-related lymphoedema market as an opportunity for growth through its SaaS subscription-based business (Appendix 4D H1 FY26, 26 Feb 2026; Q4 FY26 Appendix 4C, 28 Jul 2026).

Business and revenue model

Contract structure: Customers (predominantly US hospitals, cancer centres and integrated delivery networks) sign multi-year agreements — typically three years — that include consideration for the SOZO unit plus licence/usage fees for the contract duration (definition of Total Contracted Value, Appendix 4D H1 FY26).

Revenue recognition: Since Q2 FY24 the company reports all revenue associated with each contract as revenue from contracts with customers rather than separating "device" and "recurring subscription" revenue (Q2 FY24 Quarterly Report). Recurring usage fees are dominant: in H1 FY26, SOZO recurring usage fees were A$7.2M of A$7.5M total revenue (≈96%), up 26% YoY (Appendix 4D H1 FY26).

Key KPIs: Annual Recurring Revenue (ARR — next-12-month revenue expected from existing contracts, assuming installation and no churn), Total Contract Value (TCV — new and renewed contracts), units sold, covered lives, churn and renewal pricing.

Revenue mix (by type): Predominantly SaaS/recurring licence (≈96% in H1 FY26); small device/distributor sales (e.g., the Australian distributor's 38-unit order in Q2 FY26); legacy devices and consumables (L-Dex U400 / SFB7-era products) now immaterial; clinical-trial revenue (AstraZeneca programme) ceased in FY24.

Gross margin: High software-like gross margins — 86% (FY2023), 87% (FY2024), 86% (FY2025), 87% (FY2026) (FY24 results release; FY26 results summary).

Value-chain position

ImpediMed sits at the device-plus-software layer of the point-of-care diagnostics value chain: it owns IP, algorithms (L-Dex, HF-Dex scoring), regulatory clearances and the cloud platform, while outsourcing much of the hardware supply chain (the company referenced long-lead electronic component payments in Q1/Q2 FY26 Appendix 4C commentary). It sells direct in the US through a field sales force and via distributors elsewhere (e.g., Australia).

Customer types and end markets

Customer typeEvidence (source)
US cancer centres / breast centres172 of the top 500 US cancer centres are customers, including 24 of 33 NCCN centres (H1 FY26 investor materials as reported by StockWire X, Feb 2026)
Integrated delivery networks (IDNs)17 of the 20 top IDNs by patient revenue are customers (same source); SOZO deployed across all 15 of the top 15 US IDNs offering lifestyle medicine/primary care programmes (Appendix 4D H1 FY26)
Top US hospitalsSOZO in 18 of the top 25 US hospitals; ~600 devices deployed in the US at H1 FY26 and 642 installed at Q4 FY26
Heart failure programmesFirst Heart Health sale to an IDN in Texas (H1 FY26)
Weight-loss, lifestyle-medicine and wellness clinicsBody-composition launch, 3.5 dedicated sales reps, 3,000+ leads (H1 FY26)
International distributorsAustralian distributor ordered 38 units in Q2 FY26 (Q2 FY26 Appendix 4C)
Pharma clinical trials (historic)AstraZeneca clinical-trial programme; revenue fell from A$2.0M (FY23) to A$0.1M (FY24) (FY24 results release)

Independent characterisation

ImpediMed is effectively a single-product, single-geography (US) oncology-survivorship SaaS business with ~A$14–15M of recurring-heavy revenue, an installed base of ~640 US units, and a structurally unprofitable cost base (FY2026 operating cash burn A$17.9M). Its moat is regulatory and guideline-based rather than technological scale: it holds the only FDA-cleared BIS lymphoedema indication, has guideline endorsement (NCCN, NAPBC), a dedicated CPT code, and near-universal US payer coverage. However, conversion of that clinical/reimbursement position into unit growth has repeatedly lagged expectations (Canaccord, Feb 2026, noted the anticipated sales acceleration had yet to arrive). The diversification into heart failure and GLP-1 body composition is strategically logical (same hardware, existing hospital contracts and IT/security approvals) but is at a very early stage, while the balance sheet is fragile (going-concern doubt in FY2026 accounts, per Capital IQ headline).

Strategy

Stated strategy (themes from FY2026 reporting)

Deepen the lymphoedema/cancer-survivorship franchise: drive utilisation and growth in existing accounts; leverage NCCN/NAPBC inclusion and 95% reimbursement coverage; renewal price escalators (+14% avg Q2 FY26; +6.7% Q4 FY26).

"Three markets, one platform": extend SOZO into Heart Health (HF-Dex/SOZO Pro) and Weight Management/body composition (GLP-1 era), which management describes as capital-light because they reuse hardware, contracts and health-system approvals.

Progress toward cash-flow breakeven: A$5.0M annualised operating cost reduction (implemented Q4 FY26, realised evenly over FY27); operating cash-flow breakeven targeted in FY28 (H2 FY28 per investor presentation), assuming full exercise of options.

Commercial execution under a US medtech operator CEO: focus on health-system procurement and adoption; new sales and retention leadership roles.

Strategic partnerships: management signalled openness to partnerships (Q4 FY26 call summary).

FY27 priorities (FY26 results): deepen lymphoedema and survivorship platform; drive utilisation and growth in current accounts; scale Heart Health and Weight Management; progress toward cash-flow breakeven.

Initiatives register (last 24 months)

DateInitiativeDetail / targets
Q4 FY24 → FY25Cost reductionFY25 cash expenditure targeted −10%; achieved −16% vs FY24
Feb 2025Debt growth capitalSWK US$15M facility
FY25SOZO Pro next-gen platformIntroduced for advanced fluid and body-composition use
FY25Heart-failure evidence116-patient investigator-initiated observational HF trial
H1 FY26Heart Health commercial launchFirst IDN sale (Texas); 2 dedicated reps; THT Boston (2–4 Mar 2026)
H1 FY26Weight-management launch3.5 reps; 3,000+ leads; A$650M addressable market claim
H1 FY26Sarcopenia 510(k)Filed with FDA; outcome pending
May 2026Capital raise + cost-outA$15.2–15.3M equity; A$5.0M annualised savings; SWK amendment and A$5.0M prepayment
Jun 2026Commercial reorganisationNew leadership roles in sales and retention
Q4 FY26HF-Dex reimbursement mappingState-by-state mapping to support field activity

ESG/sustainability commitments: none specifically disclosed.

Medium-term targets / guidance

  • Operating cash-flow breakeven in FY28 (H2 FY28), contingent on full exercise of 1.32bn Attaching Options (A$0.010) and 1.32bn Follow-on Options (A$0.015), worth up to A$32.7M (4 May 2026 announcement; StockWire X).

  • No formal revenue guidance identified for FY27.

  • Earlier targets have slipped: an H2 FY24 summary referenced break-even targeted within two years, and the FY24 materials discussed moving toward cash-flow break-even — superseded by the FY28 target.

Products & Services

SOZO® (first-generation platform device)

AttributeDetail
DescriptionStanding/seated BIS device with hand and foot plates with stainless-steel electrodes; patient contacts electrodes with bare hands and feet
Key specificationsStanding weight capacity 170 kg (Stockhead, comparing to SOZO Pro)
RegulatoryFDA 510(k): K172122 (Aug 2017), K172507 (Dec 2017), K180126 (Apr 2018), K190529 (Nov 2019), K193410 (Oct 2020, "SOZO Body Fluid Analyzer"), K203473 (Apr 2021); CE-marked; ARTG-listed
IndicationsLymphoedema (L-Dex), heart failure (HF-Dex), protein-calorie malnutrition/body composition
Target customerUS cancer centres, hospitals, IDNs
Pricing modelMulti-year contract (typically 3 years) bundling unit consideration and licence/usage fees; renewal price increases averaged 14% in Q2 FY26 and 6.7% in Q4 FY26

SOZO® Pro (next-generation device)

AttributeDetail
DescriptionNext-generation BIS system with connected hand and footplate paired with an Android tablet via Bluetooth; load cells in the foot unit measure weight
Key specificationsStanding weight capacity 220 kg; updated stand design for easier transitions between standing and seated measurement (Stockhead, 2023)
RegulatorySpecial 510(k)s K230530/K230531 (4 May 2023) for lymphoedema and protein-calorie malnutrition; traditional 510(k) K232089 (17 Oct 2023) for monitoring fluid in heart-failure patients, with demonstrated compatibility with pacemakers/ICDs per ISO 14117 test methods
LaunchIntroduced in FY2025 (FY25 annual results); "SOZO Pro launched" referenced in Q2 FY26 materials; first Heart Health sale leveraged SOZO Pro (H1 FY26)
Target customerHeart-failure programmes (patients with cardiac implantable devices), oncology, weight management

MySOZO® software (cloud platform)

AttributeDetail
DescriptionCloud-based software component of the SOZO Digital Health Platform; enables measurements with either SOZO or SOZO Pro and clinician review of fluid levels
Latest versionMySOZO Software 6.0.1.2 — FDA 510(k) K253224 (predicate K232089, reference K180126)
PricingIncluded in contract licence/usage fees (SaaS)
IntegrationHealth-system Business Associate Agreements and IT-security approvals already in place across many IDNs (H1 FY26)

L-Dex® (lymphoedema index)

AttributeDetail
DescriptionProprietary BIS-derived score for early detection of extremity lymphoedema, most commonly breast-cancer-related lymphoedema
Clinical/guideline supportNCCN Survivorship Guidelines (2023, reaffirmed 2024), NAPBC standards (Oct 2024); company states it is the only FDA-cleared BIS technology for clinical lymphoedema assessment
ReimbursementCPT code 93702; US coverage 95.0% of covered lives (331M) at 30 Jun 2026, up from zero at start of FY24
Evidence baseCompany-sponsored PREVENT randomised trial (BIS-triggered vs tape-measure-triggered intervention) reported lower progression to chronic lymphoedema (2022 Annual Report narrative); details not re-verified

HF-Dex™ (heart-failure fluid index)

AttributeDetail
DescriptionFDA-cleared index derived from extracellular fluid, presenting a patient's fluid levels over time against a normal range; ~30-second, non-invasive assessment
Claimed performanceHF-Dex identified patients with 4.25× higher 30-day readmission risk vs clinical judgement alone (H1 FY26 materials as reported by StockWire X)
Commercial statusFirst sale to a Texas IDN (H1 FY26); two dedicated Heart Health reps; state-by-state HF-Dex reimbursement mapping underway (Q4 FY26); 116-patient investigator-initiated observational HF trial (FY25 annual results)
Market sizing (company)US$1.1bn heart-failure opportunity (Biotech Dispatch, citing company, FY25)

Body composition / Weight management (incl. GLP-1 monitoring) and sarcopenia

AttributeDetail
DescriptionBody-composition metrics (fat mass, fat-free/skeletal muscle mass, fluid) to monitor lean-mass loss during weight-loss therapy; company states SOZO is the only BIS device FDA-cleared to assess body composition in an unhealthy patient population
RegulatoryExisting protein-calorie malnutrition/body-composition clearances; 510(k) filed for sarcopenia indication (H1 FY26) — decision not yet disclosed
Commercial statusLaunch commenced H1 FY26; 3.5 dedicated reps; 3,000+ leads; targets weight-loss clinics, lifestyle-medicine practices and wellness clinics
Market sizing (company)~A$650M addressable market (H1 FY26); US$350M TAM in GLP-1-related body-composition scans (FY25 commentary)

Legacy products

L-Dex U400 and earlier BIS devices plus consumables (electrodes) — referenced in Morningstar's description of revenue streams ("Legacy Devices and Consumables") and the Feb 2020 release; immaterial to current revenue.

Services

Clinical-trial measurement services (historic AstraZeneca programme), customer training/implementation, and reimbursement support (company runs reimbursement initiatives to help customers update guidelines and coverage, H1 FY26).

Financial Narrative

Data notes: FY2025 and FY2026 P&L items from Appendix 4E/annual results; FY2022–FY2024 from Appendix 4E FY2023 and FY24 results release; balance sheet FY2022–FY2025 from TipRanks aggregator (cross-checked against Kalkine net-debt series and company cash disclosures); EBITDA, EPS and several ratios not disclosed in sources reviewed.

Income statement

Sources: Appendix 4E FY2023 (FY22/FY23 revenue); FY24 results release (FY24 revenue, operating loss before tax FY23/FY24, GM FY23/FY24); FY25 annual report data via financialfilings.com (FY25 revenue A$12.72M, net loss A$23.24M); Appendix 4E FY2026 (revenue A$14.613M, loss after tax A$24.907M, no dividends); FY26 results summary (GM 87% vs 86%). FY2022/FY2023 net loss from Kalkine aggregator.

Other P&L disclosures:

  • EBITDA: not publicly disclosed in reviewed documents; the business is EBITDA-negative by roughly the scale of its operating loss (FNArena shows Debt/EBITDA of −0.74).

  • H1 FY26 detail: revenue A$7.5M (+25%), gross profit A$6.6M (87%), operating expenses net of other income A$17.4M (+3%), net finance expense A$1.4M (vs A$0.4M income in H1 FY25), loss before tax A$12.3M (+10%) (Appendix 4D H1 FY26).

  • FY2026 loss increase was attributed mainly to higher finance expenses (SWK facility) (FY26 results summary).

Revenue CAGR: FY2022→FY2026 (4 years): ~8.4% (derived). FY2021→FY2026 (5 years, FY21 revenue A$8.41M per TipRanks): ~11.7% (derived). Constant-currency FY2026 growth was 20% (A$15.3M CC) (FY26 results summary).

Commentary. Revenue has compounded at high-single to low-double digits, but the trajectory masks two distinct phases: FY2022–FY2024 was distorted by the run-off of AstraZeneca clinical revenue (−A$1.9M in FY24), while SOZO Core revenue grew 30%, 14% and 25% in FY23, FY24 and FY25 respectively. FY2026's 15% reported growth (20% CC) was driven by recurring usage fees (+26% in H1), renewal price escalators and installed-base growth, partially offset by a stronger AUD in H1 and a weaker AUD later (the ARR/TCV disclosures show currency noise in both directions). Gross margins are structurally excellent (86–88%), so the loss is entirely an operating-leverage problem: operating expenses of ~A$32.7M in FY2023 (FY24 release) against ~A$11M of revenue. Net losses have widened from ~A$20M to ~A$25M as finance costs rose post-SWK draw-down.

Key operating metrics

Sources/derivations: ARR FY23 A$9.3M and FY24 A$11.0M (2024 AGM deck; FY24 release, +18%); FY25 ARR ~A$14M (Biotech Dispatch, Q4 FY25); FY26 ARR A$14.4M (Q4 FY26 Appendix 4C). FY24 TCV A$9.4M (−29%), so FY23 ≈ A$13.2M (derived). FY26 TCV derived as H1 A$8.7M + Q3 A$5.4M + Q4 A$5.4M. Units FY24 113 (−16%), so FY23 ≈ 135 (derived). Tests FY24 250k (+18%), FY23 ≈ 212k (derived). Coverage FY25 87% (Biotech Dispatch, Q4 FY25); FY24 start zero covered lives (FY24 release).

FY2026 quarterly progression

Sources: Q2 FY26 Appendix 4C (29 Jan 2026); Q4 FY26 Appendix 4C (28 Jul 2026); Quartr/TickerSpark call summaries. Derived: Q3 ARR (Q4 A$14.4M was +2% QoQ); Q2 US units (57 global less 38 Australian distributor units); Q3 operating outflow (Q4 A$4.9M was A$0.5M higher); Q3 receipts (Q4 A$4.3M was A$1.0M higher). Discrepancy: Q1 FY26 operating outflow is reported as A$5.6M in a call summary but described as A$5.9M in the Q2 4C narrative; the A$5.6M figure reconciles better to the FY total of A$17.9M. H1 cash is shown as A$18.8M in the Appendix 4D vs A$18.9M in the Q2 4C (rounding/definition).

Balance sheet

Sources: TipRanks (FY22–FY25 balances); FY25 equity, assets and net loss cross-checked to financialfilings.com (FY25 annual report); Kalkine net-debt series (−44.26, −40.56, −23.49) matches derived net cash; FY26 cash A$15.3M (Appendix 4C Q4 FY26; FY26 results); NTA per security from Appendix 4E FY2026. Short/long-term debt split, goodwill & intangibles and working capital: not publicly disclosed in reviewed sources. Pro-forma net cash after the May 2026 raise was stated at A$5.9M (raise presentation summary, InvestSMART).

Debt detail. SWK Funding LLC 5-year US$15M growth capital facility (Feb 2025): Tranche 1 US$10M drawn on signing; Tranche 2 US$5M available subject to FY25 sales targets; liquidity covenant to maintain unrestricted cash of US$2.5M; all-in cash IRR to maturity of 15.8% including interest, establishment fee and back-end success fee; 12,491,870 warrants issued at an exercise price of A$0.05139 (ASX announcement 6 Feb 2025). The facility was amended in May 2026 and A$5.0M was prepaid from the equity raise (Q4 FY26 Appendix 4C). Remaining principal at 30 Jun 2026: not publicly disclosed in sources reviewed (implied roughly A$10M based on US$10M original draw less A$5M repayment, before FX — estimate only).

Cash flow: notes and sources

Sources: FY24 results release (FY24 A$17.8M; FY23 A$18.0M); FY25 annual report via financialfilings.com (A$14.64M); FY26 results summary (A$17.9M); Kalkine aggregator for FY22 operating cash flow and FY22/FY23 free cash flow and financing flows (aggregator year labels partly inconsistent; treat as indicative). Discrepancy: the FY26 results summary cites FY25 operating outflow of A$15.6M, versus A$14.64M in the FY25 annual report data — likely a definitional difference (e.g., inclusion/exclusion of interest or R&D incentive); both are noted. Capex: not separately disclosed; aggregator FCF implies ~A$5–6M p.a. of investing outflows in FY22–FY23, consistent with capitalised SOZO units/development.

Ratios (derived from year-end figures above)

ROIC, current ratio, net debt/EBITDA, interest coverage and cash conversion cycle: not meaningful (negative EBITDA/EBIT) or not publicly disclosed. Runway derived as year-end cash ÷ (annual operating outflow ÷ 4); management cited 6.3 quarters at end-FY25 (Biotech Dispatch) and 6.5 quarters at Q2 FY26 (Quartr), consistent with this method. FY2026 runway of ~3.4 quarters on trailing burn is before the A$5M cost-out and before any option exercise.

Trend commentary

  1. Inflection in recurring revenue, not in profitability. ARR grew from A$9.3M (FY23) to A$14.4M (FY26), but ARR was flat at A$14.4M through every quarter of FY2026 in reported currency, signalling that new placements were only offsetting churn (FY26 churn rate 6.8% vs below 3% cited in FY25) and FX.

  2. Cash burn is sticky. Operating outflows have ranged A$14.6–18.0M for five consecutive years despite two cost programmes (FY25 cash opex −16%; May 2026 A$5M annualised cut).

  3. Balance-sheet deterioration. Equity fell from A$60.9M (FY23) to A$20.5M (FY25), and net tangible assets per share reached 0.00 cents at FY26. Debt became material only in FY25 (SWK), raising finance costs.

  4. Dilution as the funding mechanism. The May–June 2026 raise issued ~1.62bn shares (≈+56% on the pre-raise ~2.34bn) and up to ~2.6bn+ options; full option exercise (A$32.7M) is embedded in management's FY28 breakeven pathway.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

CategoryWhat it contains

SOZO Core Business

Revenue from SOZO contracts in the oncology/lymphoedema market (device consideration plus recurring licence/usage fees)

Clinical

SOZO use in pharma clinical trials (AstraZeneca programme; ceased FY24)

Legacy devices / other

Stand-alone legacy devices (e.g., L-Dex U400) and consumables; other income

Emerging (from FY26)

Heart Health (HF-Dex) and Weight Management/body composition — not separately quantified; described as early commercial stage

Revenue category (AUD Mn)

Revenue category (AUD Mn)FY2022FY2023FY2024FY2025FY2026

SOZO Core Business revenue

6.68.59.712.1—

Clinical revenue (AstraZeneca)

—2.00.1——

Legacy devices and other (derived = total − core − clinical)

—0.80.50.6—

Total revenue

10.5711.3410.3212.7214.61

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

SOZO Core revenue growth YoY

—301425—

SOZO Core share of total revenue

62759495—

Total revenue growth YoY

267-92315

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

10.5711.3410.3212.7214.61

Revenue growth YoY (%)

267-92315

Gross margin (%)

—86878687

Gross profit (AUD Mn, derived = revenue × GM)

—9.758.9810.9412.71

Operating loss before tax (AUD Mn, company-defined)

—-20.5-19.8——

Net loss after tax (AUD Mn)

-19.87-20.52—-23.24-24.91

Net margin (%, derived)

-188-181—-183-170

Dividends per share (AUD)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Financials and Operating Metrics (units)

MetricFY2023FY2024FY2025FY2026

SOZO Core ARR at year end (AUD Mn)

9.311.014.014.4

SOZO Core TCV signed (AUD Mn)

13.29.4—19.5

Global SOZO units sold (units)

135113——

US covered lives (millions)

0140286331

US national coverage (%)

0—8795

SOZO tests conducted (thousands)

212250——

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 FY26Q2 FY26Q3 FY26Q4 FY26

Revenue (AUD Mn)

3.63.93.53.6

ARR (AUD Mn)

14.414.414.114.4

SOZO Core TCV (AUD Mn)

4.74.15.45.4

Global units sold

4557—40

US units sold

2619—36

US national BCRL coverage (%)

8792.894.395.0

Net operating cash outflow (AUD Mn)

5.62.94.44.9

Cash receipts (AUD Mn)

—3.83.34.3

Cash at quarter end (AUD Mn)

—18.9—15.3

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash, equivalents and term deposits (AUD Mn)

40.7345.7124.6322.1815.3

Total assets (AUD Mn)

58.7068.7446.9941.66—

Total liabilities (AUD Mn)

7.667.866.2421.16—

Total debt incl. leases (AUD Mn)

0.171.451.1414.49—

Net cash (AUD Mn, cash − total debt)

40.5644.2623.497.69—

Total equity (AUD Mn)

51.0460.8840.7420.50—

Net tangible assets per share (cents)

———0.370.00

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Net operating cash flow (AUD Mn)

-15.66-18.0-17.8-14.64-17.9

Free cash flow (AUD Mn, aggregator)

-20.89-24.09———

Cash from financing (AUD Mn, aggregator)

16.4739.92———

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Gross equity raised (AUD Mn)

————15.3

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, net loss / year-end equity)

-39-34—-113—

ROA (%, net loss / year-end assets)

-34-30—-56—

Debt to equity (x)

0.000.020.030.71—

Asset turnover (x, revenue / year-end assets)

0.180.160.220.31—

Cash runway (quarters, cash / avg quarterly op. outflow)

10.410.25.56.13.4

Region revenue share (%)

Region revenue share (%)FY2024

United States (% of total revenue)

90

Rest of world incl. Australia and Europe (% of total revenue)

10

Geographic Revenue

Units soldQ1 FY26Q2 FY26Q4 FY26

US units

261936

Rest of world units

19384

Global units

455740

Valuation Snapshot

MetricValueSource / date

Last observed price

~A$0.005–0.0055

InvestSMART 22 Sep 2026; MarketScreener 3 Sep 2026

YTD 2026 return

−83.8%

MarketScreener, 3 Sep 2026

6-month return

−67.7%

MarketScreener, 3 Sep 2026

3-month return

−21.4%

MarketScreener, 3 Sep 2026

1-year return (approx.)

~−85% (≈A$0.036 at 18 Nov 2025 AGM → ≈A$0.005)

InvestSMART announcement price history (derived)

3-year return (approx.)

Deeply negative; shares traded ~A$0.08–0.24 range in late 2023/early 2024 (Google Finance year range then)

—

Placement price (May 2026)

A$0.010 (28.6% discount to A$0.014 close)

ASX 4 May 2026

SPP price (Jun 2026)

A$0.007

ASX 10 Jun 2026

Balance Sheet

MetricFY2024FY2026

Shares on issue (millions, approx.)

2,0203,660

Gross equity raised (AUD Mn)

—15.3

Valuation Multiples

MultipleImpediMedBasis

Market cap

~A$18–20M

Price × 3.66bn shares

EV/Sales (FY2026 actual)

~1.0–1.5x

MarketScreener EV A$29.4M (may be stale) vs A$14.6M revenue; MarketScreener EV/Sales FY27E 1.5x, FY28E 1.0x

P/E

Not meaningful (loss-making); MarketScreener P/E FY27E −1.65x, FY28E −3.64x

—

EV/EBITDA

Not meaningful (negative EBITDA)

—

P/B

Not meaningful (NTA per share 0.00c)

—

Peer reference

Tactile Medical: US$329.5M revenue, profitable (US$19.1M net income, 2025) — trades on positive earnings multiples; direct multiple comparison not meaningful given scale/profit gap

—

Analyst Ratings & Targets

BrokerRatingTargetDate

Canaccord Genuity

Speculative Buy

A$0.06 (cut from A$0.07)

Feb 2026

Bell Potter

Speculative Buy

—

30 Jan 2026

Morgans

Speculative Buy

—

30 Jan 2026

FNArena consensus target

—

A$0.067

Feb 2026 (pre-raise; likely stale)

Ord Minnett

Speculative Buy

—

Apr 2024

Analyst Conclusions

Management guidance

  • FY27 priorities: deepen lymphoedema/survivorship platform; increase utilisation in existing accounts; scale Heart Health and Weight Management; progress toward breakeven (FY26 results).

  • A$5.0M annualised cost savings realised evenly over the next year (Q4 FY26 call).

  • Operating cash-flow breakeven in FY28 (H2 FY28), assuming full option exercise (May 2026).

  • No explicit revenue guidance.

Consensus expectations

MarketScreener-implied consensus (via EV/Sales of 1.5x FY27E and 1.0x FY28E on ~A$29M EV) suggests revenue of roughly A$20M in FY27 and ~A$29M in FY28 — implied figures only, derived from aggregator multiples, and potentially stale or based on very limited coverage.

Bull case

  1. Reimbursement is solved; execution is the only gap. With 95% coverage, guideline status and ~700 pipeline units (vs ~642 installed), a commercially experienced CEO from Hologic's breast franchise could double the US installed base, and with 87% gross margins incremental revenue drops through powerfully.

  2. Platform optionality is cheap. HF-Dex (US$1.1bn TAM claim) and GLP-1 body composition (A$650M claim) leverage existing contracts and IT approvals; even modest traction is large relative to an ~A$20M market cap.

  3. Strategic value. Unique FDA clearances (BIS lymphoedema; HF in implantable-device patients) and a blue-chip US customer list may be worth more to a larger medtech or survivorship player than the current equity value.

Bear case

  1. Funding gap. A$15.3M cash at FY26 against ~A$18M trailing burn, a going-concern doubt, debt covenants, and option exercise prices 2–3× the share price imply further deeply dilutive capital raising.

  2. Demand has disappointed. ARR has been flat for four quarters, churn has risen to 6.8%, and despite near-universal coverage US unit sales remain ~20–40 per quarter.

  3. Competition and scale. Tactile Medical (US$329.5M revenue) now owns an assessment technology (LymphaTech) and a large lymphoedema sales channel; cheaper BIA/DXA options compete in body composition.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 2026Q1 FY27 Appendix 4C — first full quarter of cost-out; ARR and US units under new CEO
Nov 2026 (expected)2026 AGM — remuneration vote, any capital-management resolutions
FY27FDA decision on sarcopenia 510(k)
FY27Heart Health: additional IDN wins; HF-Dex reimbursement mapping outcomes
FY27Weight-management conversion from 3,000+ leads
OngoingChurn rate trajectory and renewal pricing
OngoingSWK covenant headroom; option exercise behaviour (A$0.010/A$0.015 strikes)
OngoingAny strategic partnership/M&A announcements
Feb 2027H1 FY27 results — evidence on breakeven path

Concluding analyst verdict

ImpediMed is a classic case of a clinically validated, commercially under-scaled medtech whose equity has been crushed by the cost of waiting for adoption. Every structural obstacle the company identified three years ago has been cleared: BIS is in NCCN and NAPBC guidance, a CPT code exists, US coverage has gone from zero to 95% of covered lives, and SOZO sits in the most prestigious cancer centres and IDNs in the country. Gross margins of 86–88% demonstrate that the product, once placed, is a high-quality recurring revenue stream.

Yet the financial outcome remains poor. FY2026 revenue of A$14.6M grew 15%, but ARR stalled at A$14.4M throughout the year, churn rose to 6.8%, and operating cash burn of A$17.9M exceeded revenue. The May–June 2026 recapitalisation — 1.62bn shares at A$0.007–0.010, a A$5M cost-out and partial SWK prepayment — bought time rather than solving the funding problem, and the auditor's going-concern doubt is the clearest signal of how thin the margin for error is. The FY28 breakeven target relies on option exercise at prices well above the current share price, which looks unlikely absent a sharp operational turnaround.

The investment debate therefore hinges almost entirely on whether Erik Anderson's US hospital-sales background can convert a ~700-unit pipeline into placements quickly enough to stabilise ARR growth at 20%+ before cash runs short, and whether the HF and GLP-1 adjacencies can contribute without additional fixed cost. We view IPD as a high-risk, binary, option-like security: the strategic asset value (unique clearances, guideline status, US footprint) provides a plausible floor via partnership or acquisition, but the base case for existing shareholders remains further dilution. Monitor Q1–Q2 FY27 ARR, churn and cash burn closely; absent visible acceleration, the equity is best treated as speculative only.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundSource

Erik Anderson

Managing Director & CEO

Board from 25 Feb 2026; CEO from 7 Apr 2026

Former Division President, Breast & Skeletal Health at Hologic; >25 years in US hospital sales, health-system account management and commercialisation

ASX 7 Apr 2026; Appendix 4D H1 FY26; MPO

McGregor Grant

CFO & COO, Executive Director

Board since Sep 2023 (initially Chair; Executive Chair & interim CFO from Nov 2023); CFO from Feb 2024

Board administration, governance and investor-relations experience

Strawman/Morningstar bios; InvestSMART

Leanne Ralph

Company Secretary (Bellev)

Current

Outsourced company secretarial

Appendix 4E cover letter

Dr Parmjot Bains

Former MD & CEO

Jan 2024 – 7 Apr 2026; adviser to 30 Jun 2026

Healthcare executive with strategy, sales/marketing and commercial experience across the US, Asia, Middle East and Australia

ASX 7 Apr 2026; company bio

Board of Directors

DirectorRoleAppointedBackgroundIndependence

Christine Emmanuel-Donnelly (BSc)

Non-Executive Chair

28 Sep 2023

IP specialist; former commercialisation/IP leader at CSIRO and RMIT; ex-patent attorney (AU/UK firms, Unilever UK); NED of PolyNovo, Medical Developments International, Pikcha Holdings (Seminal)

Independent

Erik Anderson

Managing Director & CEO

25 Feb 2026 (NED), CEO 7 Apr 2026

See above

Executive

McGregor Grant

Executive Director, CFO & COO

Sep 2023

See above

Executive

Andrew Grant (BEE, MBA)

Non-Executive Director

28 Sep 2023

Medical-device and hospital-sector executive across Australia, USA, Europe, Asia

—

Janelle Delaney (MBA)

Non-Executive Director

28 Sep 2023

Not detailed in sources reviewed

Independent

Fiona Bones

Non-Executive Director

7 Jun 2024

Not detailed in sources reviewed

—

Board & Management Changes

DateChange

28 Sep 2023

Four directors replaced by shareholder vote

Nov 2023

McGregor Grant Executive Chair & interim CFO; Dr Michael Seiden resigns (20 Nov 2023)

Jan 2024

Dr Parmjot Bains appointed MD & CEO

7 Jun 2024

Fiona Bones joins board

25 Feb 2026

Erik Anderson joins board

7 Apr 2026

Anderson becomes MD & CEO; Bains steps down (adviser to 30 Jun 2026)

2 Jun 2026

Two new commercial leadership roles created (sales, customer retention)

Major Shareholders

HolderStakeDate / source

Acorn Capital Limited

5.64% (131.9M shares) at time of notice; diluted post-raise (current % not disclosed)

Became substantial 7 May 2026 (FilingReader)

Australian Ethical Investment

4.73% (173.2M shares) — ceased to be substantial 1 Jul 2026

Notice 3 Jul 2026

Other top-10 holders

Not publicly disclosed in sources reviewed (see 2026 Annual Report shareholder information)

—

Free float

~92% (MarketScreener)

Sep 2026

Director holdings

Small relative to issued capital; directors subscribed A$0.6M in the May 2026 placement (Tranche 2) plus fee-for-shares issues; Chair bought 1.5M shares on 5 Feb 2026

ASX notices

Competitive Landscape

Competitors by Segment

End-marketCompetitorOfferingRelative positioning vs ImpediMed

Lymphoedema assessment

Tape measurement / limb volumetry (standard practice)

Low-cost manual circumference

Incumbent standard of care; ImpediMed's core displacement target

Lymphoedema assessment

Perometry (e.g., Pero-System)

Optoelectronic limb volume

Objective volume measure; lacks BIS's extracellular-fluid specificity

Lymphoedema assessment

Tactile Medical — LymphaTech (acquired 2025/26)

3D imaging limb measurement

New, well-funded competitor in assessment, integrated with a large lymphoedema-treatment sales force

Lymphoedema treatment (adjacent)

Tactile Medical (Flexitouch, Nimbus)

Pneumatic compression devices

US$329.5M 2025 revenue; potential partner or rival in the survivorship pathway

Lymphoedema assessment

Tissue dielectric constant devices (e.g., Delfin MoistureMeter)

Local tissue water

Niche alternative

Body composition

InBody (Korea)

Multi-frequency BIA analysers

Global leader in BIA body composition for clinics/fitness; far larger scale; lacks ImpediMed's specific FDA lymphoedema/HF claims

Body composition

seca (Germany)

Medical BIA (mBCA)

Strong hospital presence in Europe/US

Body composition

DXA (Hologic, GE HealthCare)

Dual-energy X-ray absorptiometry

Gold-standard reference; higher cost, radiation, lower throughput

Body composition / wellness

Evolt, Styku, Tanita, Bodystat, RJL Systems

Consumer/clinic BIA and 3D scanning

Price competition in GLP-1/wellness channel

Dialysis/fluid

Fresenius Body Composition Monitor

BIS in renal care

Adjacent BIS application

Heart failure monitoring

Abbott CardioMEMS

Implantable pulmonary-artery pressure sensor

Evidence-rich, invasive, premium

Heart failure monitoring

Sensible Medical (ReDS)

Non-invasive lung fluid measurement

Direct non-invasive fluid competitor

Heart failure monitoring

Bodyport (Cardiac Scale)

FDA-cleared impedance scale (same DSB product code)

Home-based remote monitoring competitor

Heart failure monitoring

Device-based (e.g., Medtronic OptiVol in implantables), ZOLL HFMS

Embedded/wearable fluid metrics

Integrated with cardiology workflows

Peer Comparison FY2026

MetricImpediMed (FY2026, A$)Tactile Medical (FY2025, US$)

Revenue

14.6M

329.5M

Revenue growth

15%12%

Gross margin

87%75.9%

Operating margin

≈ −160% (derived, loss-making)

8.9% (US$29.3M operating income)

Net income

−24.9M

19.1M

R&D intensity

—

2.6% (US$8.5M)

“—” = not publicly disclosed.

Recent Developments

--

Company Snapshot

$9.4M

Revenue

76

Employees

1999

Founded

Pinkenba, Australia

Headquarters

SWOT Analysis

Strengths

  • Unique regulatory position: only FDA-cleared BIS technology for clinical lymphoedema assessment (company boilerplate, H1 FY26).
  • Guideline endorsement: NCCN Survivorship Guidelines (2023, reaffirmed 2024) and NAPBC standards (Oct 2024) reference BIS.
  • Reimbursement breadth: 95.0% national US coverage, 331M covered lives, 47 states above 90% (Q4 FY26 Appendix 4C).
  • High gross margin: 87% in FY2026 (FY26 results).
  • Recurring revenue quality: recurring usage fees A$7.2M of A$7.5M H1 FY26 revenue; renewal price increases of 14% (Q2) and 6.7% (Q4).
  • Blue-chip footprint: 18 of top 25 US hospitals; 24 of 33 NCCN centres; 17 of top 20 IDNs (H1 FY26 materials).

Weaknesses

  • Persistent losses: net loss A$24.9M in FY2026, up from A$23.2M (Appendix 4E FY2026).
  • High burn vs revenue: operating cash outflow A$17.9M vs revenue A$14.6M (FY26).
  • Stalled ARR: A$14.4M at Q2, ~A$14.1M at Q3 and A$14.4M at Q4 FY26 — no reported-currency growth across H2.
  • Rising churn: 6.8% in FY26 vs below 3% cited in FY25 (Biotech Dispatch).
  • Eroded equity: NTA per share 0.00 cents at 30 Jun 2026 (vs 0.37c); equity A$20.5M at FY25 vs A$60.9M at FY23.
  • Leadership churn: three CEOs in roughly three years (Valencia → Bains → Anderson) and a fully replaced board since 2023.

Opportunities

  • Pipeline conversion: ~700 US opportunity units (>US$35M potential TCV) vs ~600–642 installed (H1/Q4 FY26).
  • Heart failure: company-stated US$1.1bn opportunity; clearance for patients with implantable devices (K232089).
  • GLP-1 body composition: A$650M addressable market claim; 3,000+ leads; sarcopenia 510(k) pending.
  • Cross-sell into existing IDNs: BAAs/IT approvals already in place at all top-15 lifestyle-medicine IDNs.
  • Option-funded capital: up to A$32.7M from Attaching/Follow-on options if exercised.
  • Strategic interest: sub-A$20M market cap with unique clearances could attract a partner/acquirer (management references partnership opportunities, Q4 FY26) — speculative.

Threats

  • Going-concern doubt in FY26 accounts (Capital IQ, 26 Aug 2026).
  • Debt covenants: SWK requires US$2.5M minimum unrestricted cash; 15.8% all-in IRR raises cost of capital.
  • Option exercise risk: exercise prices A$0.010/A$0.015 are well above the ~A$0.005 share price (Sep 2026), threatening the FY28 breakeven funding assumption.
  • Competitive entry: Tactile Medical's LymphaTech acquisition brings a scaled competitor (US$329.5M revenue) into lymphoedema assessment.
  • Severe dilution: ~1.62bn new shares in mid-2026 plus option overhang; share price −84% YTD to Sep 2026.
  • FX exposure: USD-earning, AUD-reporting; reported ARR swung by ~A$0.2M between reported and constant currency in Q4 FY26.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jul 2025Q4 FY25: record TCV A$6.3M; revenue A$3.3M; ARR ~A$14M; 44 US units incl. 9-unit Legacy Health deal; cash A$22.2M (6.3 quarters)Peak commercial momentum quarter
Jul 2025Australian Ethical sells down part of holdingInstitutional rotation
28 Aug 2025FY25 results: revenue A$12.7M (+23%), core A$12.1M (+25%), covered lives 286M, cash opex −16%; SOZO Pro introducedBest growth year; reimbursement inflection
Sep 2025AGM date set (18 Nov 2025); director nominations windowGovernance calendar
Oct 2025Q1 FY26: revenue A$3.6M; coverage 87%; 45 units (26 US); TCV A$4.7M; op. outflow ~A$5.6M incl. long-lead componentsUS unit sales softer
18 Nov 20252025 AGM held onlineRoutine
Dec 2025 – Jan 2026SOZO Pro launched commercially (Q2 FY26 summary)Enables HF market entry
14–16 Jan 2026Securities quotation/cessation noticesRoutine capital management
29 Jan 2026Q2 FY26: record revenue A$3.9M (+18% YoY); coverage 92.8% (323M lives); 57 units incl. 38 to Australian distributor; renewal pricing +14%; R&D incentive A$1.2M; cash A$18.9MRecord quarter but US units only ~19
30 Jan 2026Bell Potter and Morgans rate IPD Speculative BuyBroker support
5 Feb 2026Chair buys 1.5M shares (~A$29k)Insider confidence signal
Feb 2026Canaccord retains Speculative Buy, cuts target to 6c from 7c; highlights balance-sheet riskSell-side caution
25 Feb 2026Erik Anderson appointed independent NEDUS commercial expertise added
26 Feb 2026H1 FY26: revenue A$7.5M (+25%); ARR A$14.4M (+15%); TCV A$8.7M (+9%); loss before tax A$12.3M; coverage 93%; first Heart Health sale; weight-management launch; sarcopenia 510(k) filed; ~700-unit pipeline (>US$35M TCV)Platform diversification begins
2–4 Mar 2026First dedicated heart-failure conference (THT Boston)HF go-to-market
3 Mar 2026H1 investor presentation—
7 Apr 2026Anderson appointed MD & CEO; Bains to adviser role until 30 JunLeadership reset toward US execution
30 Apr 2026Q3 FY26: revenue A$3.5M; coverage 94.3%; ARR ~A$14.1MSequential dip
4 May 2026A$15.2M raise at A$0.010 (28.6% discount); A$5M cost-out; SWK amendment; FY28 breakeven targetHighly dilutive rescue-style financing; share price collapsed from A$0.014 toward A$0.005
7 May 2026Tranche 1 settlement (A$3.0M); Acorn Capital becomes 5.64% holderNew institutional support
2 Jun 2026CEO business update: two new leadership roles; positive unit momentum; conference engagementCommercial restructuring
5–10 Jun 2026SPP closes oversubscribed at A$2.1M (A$0.007/share + options)Retail support
11 Jun 2026EGM approves Tranche 2, director participation and optionsFunding secured
16–18 Jun 2026New shares quoted; Australian Ethical substantial-holding notices (8.02% then corrected to 5.13%)Register changes
30 Jun 2026Dr Bains' employment concludesTransition complete
1–3 Jul 2026Australian Ethical ceases to be substantial (4.73%); NEDs take 15% of fees in sharesInstitutional exit; director alignment
28 Jul 2026Q4 FY26: revenue A$3.6M (+3% QoQ); ARR A$14.4M (A$14.6M CC); TCV A$5.4M; 40 units (36 US); record receipts A$4.3M; op. outflow A$4.9M; cash A$15.3M; coverage 95.0% (331M); A$5.0M SWK prepaymentUS units recover; burn still high
13 Aug 2026ASX Listing Rule 7.16 compliance noticeSecurities/option administration
26 Aug 2026Auditor raises going-concern doubt (Capital IQ headline)Key solvency flag
27 Aug 2026FY26 Appendix 4E and Annual Report: revenue A$14.6M (+15%); net loss A$24.9M; NTA 0.00c; churn 6.8%Year-end confirmation
11 Sep 2026Notice of 2026 AGM date–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue Category: Total revenue rose from AUD 10.6 Mn in FY2022 to AUD 14.6 Mn in FY2026.
ImpediMed Limited — Revenue Category
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue10.611.310.312.714.6
SOZO Core Business revenue6.68.59.712.1—
Clinical revenue (AstraZeneca)—20.1——
Legacy devices and other ( = total − core − clinical)—0.80.50.6—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ImpediMed Appendix 4E, FY ended 30 Jun 2026 (ASX, 27 Aug 2026)
  2. ImpediMed FY26 Half Year Financial Results / Appendix 4D (ASX, 26 Feb 2026)
  3. ImpediMed Q4 FY26 Quarterly Activity and Cash Flow Report (ASX, 28 Jul 2026)
  4. ImpediMed Q2 FY26 Quarterly Activity and Cash Flow Report (ASX, 29 Jan 2026)
  5. ImpediMed Appointment of CEO/MD (ASX, 7 Apr 2026)
  6. ImpediMed press release, Erik Anderson appointment
  7. ImpediMed capital raise announcement (ASX, 4 May 2026)
  8. ImpediMed SWK growth capital facility (ASX, 6 Feb 2025)
  9. ImpediMed FY25 annual results (ASX, 28 Aug 2025)
  10. ImpediMed FY24 results (ASX, 29 Aug 2024)
  11. ImpediMed 2024 AGM CEO slide deck
  12. ImpediMed FY2023 Appendix 4E
  13. ImpediMed Q2 FY24 Report
  14. ImpediMed 2023 AGM Chair's Address (ASX, 30 Nov 2023)
  15. ImpediMed 2022 Annual Report (ASX, 29 Aug 2022)
  16. ImpediMed ASX release, 20 Feb 2020
  17. Quartr event summaries (H2 FY26, Q4 FY26) · quartr.com
  18. FilingReader (FY26 results; substantial holder notices)
  19. InvestSMART IPD announcements and directors
  20. MarketScreener IPD quote page
  21. FNArena IPD broker data
  22. TipRanks IPD financials
  23. Kalkine IPD financial data
  24. financialfilings.com IPD profile
  25. Morningstar IPD profile
  26. FDA 510(k) records (K172507 and related: K232089 · K253224) · 510k.innolitics.com · 510k.innolitics.com
  27. Stockhead (SOZO Pro clearance: HF-Dex clearance) · stockhead.com.au
  28. InQueensland (2023 board requisition)
  29. Biotech Dispatch (Q4 FY25 update)
  30. StockWire X (H1 FY26 and raise detail) · stockwirex.com
  31. Tactile Systems Technology FY2025 Form ARS and Q4 2025 release · investors.tactilemedical.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.